Lannett Company, Inc. Receives Approval For Doxycycline Monohydrate

PHILADELPHIA--(BUSINESS WIRE)--Dec. 12, 2005--Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Doxycycline Monohydrate Tablets 50mg and 100mg; the first generic approval of this product. Doxycycline Monohydrate is the generic version of Adoxa(R), marketed by Doak Dermatologics, a subsidiary of Bradley Pharmaceuticals, Inc. According to NDC Health, total sales of Adoxa were $32 million in 2004. Doxycycline Monohydrate is a tetracycline-type antibiotic used to treat many different bacterial infections, such as urinary tract infections, acne, gonorrhea, chlamydia, periodontitis and others.

Back to news